SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study.

Belcastro, V; Pisani, LR; Bellocchi, S; Casiraghi, P; Gorgone, G; Mula, M; Pisani, F (2017) Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study. J Neurol, 264 (5). pp. 921-927. ISSN 1432-1459 https://doi.org/10.1007/s00415-017-8463-6
SGUL Authors: Mula, Marco

[img]
Preview
PDF Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (530kB) | Preview

Abstract

To explore possible correlations among brain lesion location, development of psychiatric symptoms and the use of antiepileptic drugs (AEDs) in a population of patients with brain tumor and epilepsy. The medical records of 283 patients with various types of brain tumor (161 M/122 F, mean age 64.9 years) were analysed retrospectively. Patients with grade III and IV glioma, previous history of epileptic seizures and/or psychiatric disorders were excluded. Psychiatric symptoms occurring after initiation of AED therapy were considered as treatment emergent psychiatric adverse events (TE-PAEs) if they fulfilled the following conditions: (1) onset within 4 weeks after the beginning of AED therapy; (2) disappearance on drug discontinuation; (3) absence of any other identified possible concurrent cause. The possible influence of the following variables were analysed: (a) AED drug and dose; (b) location and neuroradiologic features of the tumor, (c) location and type of EEG epileptic abnormalities, (d) tumor excision already or not yet performed; (e) initiation or not of radiotherapy. TE-PAEs occurred in 27 of the 175 AED-treated patients (15.4%). Multivariate analysis showed a significant association of TE-PAEs occurrence with location of the tumor in the frontal lobe (Odds ratio: 5.56; 95% confidence interval 1.95-15.82; p value: 0.005) and treatment with levetiracetam (Odds ratio: 3.61; 95% confidence interval 1.48-8.2; p value: 0.001). Drug-unrelated acute psychiatric symptoms were observed in 4 of the 108 AED-untreated patients (3.7%) and in 7 of the 175 AED-treated patients (4%). The results of the present study suggest that an AED alternative to levetiracetam should be chosen to treat epileptic seizures in patients with a brain tumor located in the frontal lobe to minimize the possible onset of TE-PAEs.

Item Type: Article
Additional Information: The final publication is available at Springer via http://dx.doi.org/10.1007/s00415-017-8463-6
Keywords: Epilepsy, Levetiracetam, Psychiatric adverse events, Tumor frontal lobe location, Tumor frontal lobe location, Epilepsy, Levetiracetam, Psychiatric adverse events, Neurology & Neurosurgery, 1103 Clinical Sciences, 1109 Neurosciences
SGUL Research Institute / Research Centre: Academic Structure > Institute of Medical & Biomedical Education (IMBE)
Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Clinical Education (INMECE )
Journal or Publication Title: J Neurol
ISSN: 1432-1459
Language: eng
Dates:
DateEvent
May 2017Published
18 March 2017Published Online
14 March 2017Accepted
Publisher License: Publisher's own licence
PubMed ID: 28315958
Web of Science ID: WOS:000400617200012
Go to PubMed abstract
URI: http://openaccess.sgul.ac.uk/id/eprint/108883
Publisher's version: https://doi.org/10.1007/s00415-017-8463-6

Actions (login required)

Edit Item Edit Item